Trevi Therapeutics, Inc. (TRVI)
Last updated: 2026-10-21 16:00:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Trevi Therapeutics, Inc. (TRVI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $13.05, with a market capitalization of $1.70B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9.82 to $20.22. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.70B | |
$12.77 | |
$20.22 | |
$0.46 | |
$12.83 | |
741.97K | |
1.97M | |
-- | |
$20.22 | |
$9.82 | |
-- | |
-- |
Trevi Therapeutics, Inc. (TRVI) Stock Price Today
Trevi Therapeutics, Inc. (TRVI) is currently trading at $13.05 as of 2026-10-21 15:59:00, up 1.68% ($0.21) from the previous close of $12.83
During today's regular trading session, TRVI has traded between $0.46 and $20.22, with a trading volume of 741.97K shares. The current price is near the middle of today's range.
Trevi Therapeutics, Inc. (TRVI) 7-Day Stock Price Change
Over the past seven days, Trevi Therapeutics, Inc. (TRVI) moved from $12.93 to $13.05, representing a gain of 0.89% ($0.12).
The stock traded between $11.70 and $13.46 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 2.46 million shares, down versus the previous seven-day period, indicating lower trading activity.
TRVI 52-Week Price Position
Position in Range: 31.0%
TRVI is currently trading at $13.05, placing it 31.0% of the way from its 52-week low of $9.82 to its 52-week high of $20.22. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Trevi Therapeutics, Inc. (TRVI)?
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Trevi Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 34 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Trevi Therapeutics, Inc. (TRVI) Stock on MEXC
Eligible investors can buy real shares of Trevi Therapeutics, Inc. (TRVI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Trevi Therapeutics, Inc. (TRVI) stock price today?
2.Is TRVI stock going up or down today?
3.What is TRVI pre-market price?
4.What is TRVI after-hours price?
5.Is TRVI stock trading now?
6.Where does TRVI sit relative to its 52-week high and low?
7.What sector is Trevi Therapeutics, Inc. in?
8.What is Trevi Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is TRVI valued in terms of P/E ratio and EPS?
10.Does Trevi Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
TRVI Stock Calculator
Estimate the value between TRVI shares and USD.
TRVI Shares to USD
1.00 TRVI shares = 13.045 USD
Calculations are estimates based on the latest available price and are for reference only.


